Lower risks of cirrhosis and hepatocellular carcinoma with GLP‐1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: To assess the association of cirrhosis and hepatocellular carcinoma (HCC) with the use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) versus long‐acting insulins (LAIs), which are the two commonly prescribed injectable glucose‐lowering agents (GLAs) for patients with type 2 diabetes (T2D) after the failure of multiple oral GLAs. Methods: We emulated a target trial using the nationwide data of a Taiwanese cohort with T2D. Incident new users of GLP‐1RAs and LAIs during 2013–2018 were identified, and propensity score (PS) matching was applied to ensure between‐group comparability in baseline patient characteristics. The primary outcome was the composite liver disease including cirrhosis or HCC. Each patient was followed until the occurrence of a study outcome, death, or the end of 2019, whichever came first. Subdistribution hazard models were employed to assess the treatment‐outcome association. Sensitivity (e.g., stabilized inverse probability of treatment weighting analysis, time‐dependent analysis), E‐value, and negative control outcome analyses were performed to examine the robustness of study findings. Results: We included 7171 PS‐matched pairs of GLP‐1RA and LAI users with no significant between‐group differences at baseline. Compared with LAIs, the use of GLP‐1RAs was associated with significantly reduced risks of composite liver disease (subdistribution hazard ratio [95% confidence interval]: 0.56 [0.42–0.76]), cirrhosis (0.59 [0.43–0.81]), and HCC (0.47 [0.24–0.93]). Results were consistent across sensitivity analyses and among patients with different baseline characteristics. Conclusion: Among T2D patients who require injectable GLAs, the use of GLP‐1RAs versus LAIs was associated with lower risks of cirrhosis and HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350 · cited 1×
“Sixth, an E -value analysis was conducted to assess how strongly a potential unmeasured confounder would negate the observed treatment-outcome association [27, 28].”
MethodIntroduction to the Analysis of Survival Data in the Presence of Competing Risks
Austin, P. C., Lee, D. S., & Fine, J. P. (2016) · Circulation · doi:10.1161/circulationaha.115.017719 · Cited by 2,653
Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies
Lipsitch, M., Tchetgen Tchetgen, E., & Cohen, T. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181d61eeb · Cited by 1,583 · cited 1×
“…ratio of 2.94 was close to the estimated E -value of 2.97 and our hypothetical calculation only accounted for residual confounding by HbA1c levels, we further performed a negative control outcome analysis to detect the possibility of residual confounding effects in this observational study [30].”
InfluentialRandomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Lund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739 · cited 1×
“We excluded patients receiving GLP-1RAs or LAIs in the year before the index date [17].”
BackgroundAMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer
Hardie, D. G. (2013) · Diabetes · doi:10.2337/db13-0368 · Cited by 458 · cited 1×
“…the direct effects of GLP-1RAs on the attenuation of hepatocyte apoptosis [41, 42], the modulation of liver Kupffer cell M1/M2 polarization [43, 44], and the activation of AMP-activated protein kinase, which is associated with anti-inflammation and the prevention of cancer development [45, 46].”
BackgroundHeerspink, H. J. L., Karasik, A., Thuresson, M., Melzer-Cohen, C., Chodick, G., Khunti, K., Wilding, J. P. H., Garcia Rodriguez, L. A., Cea-Soriano, L., Kohsaka, S., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30384-5 · Cited by 317
Koutoukidis, D. A., Koshiaris, C., Henry, J. A., Noreik, M., Morris, E., Manoharan, I., Tudor, K., Bodenham, E., Dunnigan, A., Jebb, S. A., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154455 · Cited by 186
Wu, C.-Y., Iskander, C., Wang, C., Xiong, L. Y., Shah, B. R., Edwards, J. D., Kapral, M. K., Herrmann, N., Lanctôt, K. L., Masellis, M., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1705 · Cited by 139 · cited 1×
“The 1-year time period has been commonly applied in the literature to assess patients’ baseline status and further determine the incident use of study treatments among real-world T2D populations [18–21].”
MethodPatorno, E., Htoo, P. T., Glynn, R. J., Schneeweiss, S., Wexler, D. J., Pawar, A., Bessette, L. G., Chin, K., Everett, B. M., & Kim, S. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0893 · Cited by 103
Cited by
Elsaid, M. I., Li, N., Firkins, S. A., Rustgi, V. K., Paskett, E. D., Acharya, C., Reddy, K. R., Chiang, C. W., & Mumtaz, K. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17925 · Cited by 77
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“Although not specifically indicated for MASH [2], GLP1-RAs have also reduced the risk of composite liver disease (including cirrhosis or HCC) in patients with diabetes [322–324], even in those with compensated cirrhosis from MASLD [325].”
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
Metadata
- Authors
- Yang, C., Yao, W., Yang, C., Peng, Z., Ou, H., & Kuo, S.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2023-11-22
- Volume
- 295
- Issue
- 3
- Pages
- 357-368
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W4388952380
- Cited by
- 42
- References
- 15
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.